Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine for Bipolar I Disorder relapse prevention
NCT01602510Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Lamotrigine Arm with Placebo Arm (2 arms). Primary endpoint: Time to Intervention for Any Mood Episode at 36 weeks. Started Aug 2012; status: completed.
02
Drugs
lamotrigine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT01602510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602510.